Related Topics News -

     
 Title only   |   Print 
     
恆瑞醫藥子公司HRS9531注射液獲准開展臨床試驗

2026-04-20T  
恆瑞醫藥瑞康曲妥珠單抗獲納入突破性治療品種名單

2026-04-20T  
恆瑞醫藥向股東派末期息20分人幣

2026-04-20T  
恆瑞醫藥SHR-A2102獲納入突破性治療品種名單

2026-04-16T  
恆瑞醫藥子公司HRS-7156片臨床試驗獲批

2026-04-15T  
工信部:正編制醫藥工業「十五五」發展規劃 推動優質優價藥品早日上市供應

2026-04-15T  
恆瑞醫藥HRS-5765片臨床試驗獲批

2026-04-10T  
恆瑞醫藥HRS9531注射液獲批開展臨床試驗

2026-03-26T  
《業績》恆瑞醫藥去年純利77.11億人民幣升21.7% 末期息20分

2026-03-26T  
恆瑞醫藥向上海瑞宏迪增資2.85億人民幣

2026-03-26T  

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.